EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark INTRABIO was filed as Word mark on 08/17/2017 at the European Union Intellectual Property Office.
It was registered as a trademark on 12/13/2017.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 017126384 |
| Application date | August 17, 2017 |
| Publication date | September 5, 2017 |
| Entry date | December 13, 2017 |
| Expiration date | August 17, 2027 |
Trademark owner
Summit House, 170 Finchley Road
NW3 6BP London
GB
NW3 6BP London
GB
Trademark representatives
Bischoffsheimlaan 15
1000 Brussels
BE
goods and services
5
Pharmaceutical preparations; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for the prevention of diseases of the nervous system; Pharmaceutical preparations for treating sensory organ disorders; Pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases; Pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; Drugs for medical purposes; Drugs for medical purposes, namely the prevention and treatment of neurodegenerative diseases; Drugs for medical purposes, namely the prevention and treatment of neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; Reagents for use in medical genetic testing; Diagnostic reagents for medical laboratory use; Diagnostic reagents for medical laboratory use, namely use in the detection and identification of neurodegenerative diseases; Diagnostic reagents for medical laboratory use, namely use in the detection and identification of neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; Amino acid preparations for medical purposes; Amino acid preparations for pharmaceutical use
42
Scientific and technological services and research and design relating thereto; industrial analysis and research services; Scientific and technological services and research in the field of neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; industrial analysis and research services related to neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; design and development of computer hardware and software related to assays; Clinical trials; Conducting clinical trials for pharmaceutical products; Conducting clinical trials for neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; Medical laboratories for research related to neurodegenerative diseases, namely lysosomal storage disorders, Niemann-Pick disease, Alzheimer's disease, Parkinson's disease, prion disease, motor neurone disease, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; Providing information about the results of clinical trials for pharmaceutical products; Clinical research; Medical laboratories; Research relating to molecular sciences; Medical research; Genetic research; Research in the field of gene therapy; Biopharmaceutical research for development of targeted therapies for use in the treatment of carcinomas and neurodegenerative diseases; scientific, biochemical, research and development services in the field of neurodegenerative diseases; Providing scientific information in the field of medical disorders and their treatment; Pharmaceutical drug development services
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| January 7, 2021 | Change Representative, Published | ||
| January 5, 2021 | Change Representative, Published | ||
| May 18, 2018 | Registration, Published |
ID: 11017126384